肺癌分子靶点治疗的研究进展(9)
37Mitchell, FM, Heasley, LE, Qian, N-X, et al. Differential modulation of bombesin-stimulated phospholipase Cb and mitogen-activated protein kinase activity by [D-arg1, D-Phe5, D-Trp7,9, Leu11] substance P. J Biol Chem,1995, 270(15):8623-8628
38Dhanasekaran, N, Heasley, LE, Johnsen, GL . G-protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev ,1995,16(3):259-270
39Chambers, AF, Matrisian, LM. Changing views of the role of matrix metalloproteinases in metastases. J Natl Cancer Inst ,1997,89(17):1260-1270
, 百拇医药
40Sledge, GWJ, Qulali, M, Gailet, R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastases in athymic mice. J Natl Cancer Inst ,1995,87(20):1546-1550
41Davies, B, Brown, PO, East, N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res,1993,53(9):2087-2091
42Steward WP, Thomas AL. Marimastat the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs ,2000,9(12):2913-2922
, 百拇医药
43Folkman, J. Clinical application of research on angiogenesis. N Engl J Med ,1995,333(26):1757-1763
44Presta, LG, Chen, H, O'Connor, SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57(2):4593-4599
45Herbst RS, Hidalgo M, Pierson AS, et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol,2002 ,29(1 Suppl 4):66-77
, 百拇医药
46O'Reilly, MS, Goehm, T, Shing, Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell,1997,88(2):277-285
47Boehle AS, Kurdow R, Schulze M, et al. Neumaier Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer,2001,94(3):420-428
48Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2001,34 (Suppl 3):S81-9
, 百拇医药
49Grant, S, Jarvis, WD . Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res,1996, 2(12):1915-1920
50Prendiville, J, Crowther, D, Thatcher, N, et al. A phase I study of intravenous bryostatin I in patients with advanced cancer. Br J Cancer,1993,68(2);418-424
51Zochbauer-Muller S, Minna JD. The biology of lung cancer including potential clinical applications. Chest Surg Clin N Am, 2000,10(4):691-708
52Sarvesvaran J, Going JJ, Milroy R, et al. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis,1999,20(8):1649-1651, http://www.100md.com(乔贵宾 吴一龙)
38Dhanasekaran, N, Heasley, LE, Johnsen, GL . G-protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev ,1995,16(3):259-270
39Chambers, AF, Matrisian, LM. Changing views of the role of matrix metalloproteinases in metastases. J Natl Cancer Inst ,1997,89(17):1260-1270
, 百拇医药
40Sledge, GWJ, Qulali, M, Gailet, R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastases in athymic mice. J Natl Cancer Inst ,1995,87(20):1546-1550
41Davies, B, Brown, PO, East, N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res,1993,53(9):2087-2091
42Steward WP, Thomas AL. Marimastat the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs ,2000,9(12):2913-2922
, 百拇医药
43Folkman, J. Clinical application of research on angiogenesis. N Engl J Med ,1995,333(26):1757-1763
44Presta, LG, Chen, H, O'Connor, SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57(2):4593-4599
45Herbst RS, Hidalgo M, Pierson AS, et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol,2002 ,29(1 Suppl 4):66-77
, 百拇医药
46O'Reilly, MS, Goehm, T, Shing, Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell,1997,88(2):277-285
47Boehle AS, Kurdow R, Schulze M, et al. Neumaier Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer,2001,94(3):420-428
48Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2001,34 (Suppl 3):S81-9
, 百拇医药
49Grant, S, Jarvis, WD . Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res,1996, 2(12):1915-1920
50Prendiville, J, Crowther, D, Thatcher, N, et al. A phase I study of intravenous bryostatin I in patients with advanced cancer. Br J Cancer,1993,68(2);418-424
51Zochbauer-Muller S, Minna JD. The biology of lung cancer including potential clinical applications. Chest Surg Clin N Am, 2000,10(4):691-708
52Sarvesvaran J, Going JJ, Milroy R, et al. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis,1999,20(8):1649-1651, http://www.100md.com(乔贵宾 吴一龙)